LivsMed

At a glance

LivsMed filed 51 disclosures in the last 12 months, including 14 insider, 11 5% holder and 1 m&a. The most recent key filing was on Jul 10.

Revenue for 2025 was ₩51.2B, up 88.8% on 2024. It made an operating loss of ₩22.6B. Debt was 12% of equity at year end. The latest interim report (2026 H1) shows revenue of ₩22.8B and operating loss of ₩20.6B.

The 2025 annual report lists 334 employees with an average tenure of 1.4 years and average pay of ₩44.3M, #1666 of 1,829 listed companies by average pay. Its 7 directors and auditors were paid ₩132M each on average. It paid no cash dividend for 2025. 이정주 and related parties held 39.41% at year end.

From the 2025 annual report

Staff: 334 (230 men, 104 women), of whom 63 on fixed-term contracts. Total pay for the year: ₩14.5B. Directors and auditors: 7, paid ₩837M in total.

No cash dividend was paid for 2025.

Largest shareholder

이정주 holds 39.33%; with 1 related party the group holds 39.41% of common shares at year end (from 45.35% at the start of the year).

Auditor: 삼일회계법인 · opinion: Unqualified.

Source: 2025 annual business report (DART). How figures are combined

Financial summary